JAN 05, 2022
CMS Extends IRIS Registry’s Status for MIPS Data Collection
For the sixth year in a row, the Centers for Medicare & Medicaid Services (CMS) has approved the IRIS® (Intelligent Research in Sight) Registry as a qualified clinical data registry (QCDR), defined as an entity with demonstrated clinical expertise in medicine and quality measure development, for the 2022 Merit-Based Incentive Payment System (MIPS) program.
CMS approved 26 ophthalmology QCDR measures that are only available for IRIS Registry participants.
Only CMS-approved registries can report data, quality measures and/or activities for the quality, promoting interoperability and improvement activities performance categories. This means that the IRIS Registry can collect clinical data for MIPS and report to CMS on behalf of eligible clinicians and groups.